KRON - Kronos Bio

-

$undefined

N/A

(N/A)

Kronos Bio NasdaqCM:KRON Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule therapeutics to treat cancer and other serious diseases in the United States. It is developing KB-9558, a p300 KAT inhibitor development candidate which is in preclinical development for the treatment of multiple myeloma, as well as HPV-driven tumors; and KB-7898, a p300 KAT inhibitor, which is in preclinical development for the treatment of Sjogren's disease. The company was incorporated in 2017 and is headquartered in San Mateo, California.

Location: 1300 So. El Camino Real, San Mateo, CA, 94402, United States | Website: https://www.kronosbio.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

NaN

52 Wk Range

$ - $

Previous Close

$N/A

Open

$N/A

Day Range

N/A - N/A

Volume

N/A

Avg Volume

N/A

Enterprise Value

-34.7M

Cash

99.73M

Avg Qtr Burn

-13.59M

Short % of Float

1.25%

Insider Ownership

24.31%

Institutional Own.

31.44%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.